TY  - JOUR

T1  - The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.

JO  - Health Technol Assess

PY  - 2013/04/01

AU  - Hoyle M

AU  - Crathorne L

AU  - Peters J

AU  - Jones-Hughes T

AU  - Cooper C

AU  - Napier M

AU  - Tappenden P

AU  - Hyde C

ED  - 

DO  - DOI: 10.3310/hta17140

VL  - 17

IS  - 14

SP  - 1

EP  - 237

Y2  - 2024/12/26

ER  -